Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity

Lung cancers bearing oncogenic EML4-ALK fusions respond to targeted tyrosine kinase inhibitors (TKIs; e.g., alectinib), with variation in the degree of shrinkage and duration of treatment (DOT). However, factors that control this response are not well understood. While the contribution of the immune...

Descripción completa

Detalles Bibliográficos
Autores principales: Kleczko, Emily K., Hinz, Trista K., Nguyen, Teresa T., Gurule, Natalia J., Navarro, Andre, Le, Anh T., Johnson, Amber M., Kwak, Jeff, Polhac, Diana I., Clambey, Eric T., Weiser-Evans, Mary, Merrick, Daniel T., Yang, Michael C., Patil, Tejas, Schenk, Erin L., Heasley, Lynn E., Nemenoff, Raphael A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899278/
https://www.ncbi.nlm.nih.gov/pubmed/36739466
http://dx.doi.org/10.1038/s41698-023-00355-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899278/
https://www.ncbi.nlm.nih.gov/pubmed/36739466
http://dx.doi.org/10.1038/s41698-023-00355-2

Ejemplares similares